VivoSeq
Oncology

Hodgkin Lymphoma

24

Pipeline Programs↗

4

Active Trials↗

16

Companies Involved↗

Hodgkin Lymphoma is an emerging landscape with 24 programs across 16 companies. The most active players are Merck & Co., Johnson & Johnson, Gilead. 17 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3E

Eastern Cooperative Oncology Group

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

18 of 23 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody313%Antibody–drug conjugate14%Protein / enzyme14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Active, not recruiting1 · 17%
Terminated1 · 17%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Recruiting·National Cancer Institute (NCI)·Phase 3·NCT05675410·1,875 enrolled
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma
Recruiting·UUniversity College, London·Phase 3·NCT04685616·1,042 enrolled
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03618550·257 enrolled
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03179917·22 enrolled
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Completed·CColumbia University·Preclinical·NCT01657331·65 enrolled
A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Terminated·SStanford University·Phase 2·NCT04788043·8 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)